CHUY stock was delisted from NASDAQ on
Oct 10, 2024. You can explore more stocks from
Consumer Cyclical sector on this page.
Have a feature idea you'd love to see implemented?
Let us know!
CODX Co-Diagnostics Inc
Price (delayed)
$1.245
Market cap
$39.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$28.45M
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using
Highlights
The company's gross profit has surged by 98% QoQ and by 8% YoY
The revenue has grown by 37% from the previous quarter and by 25% YoY
Co-Diagnostics's gross margin has increased by 45% QoQ but it has decreased by 14% YoY
Co-Diagnostics's quick ratio has decreased by 38% YoY and by 10% QoQ
The equity has declined by 30% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of CODX
Market
Valuations
Earnings
Shares outstanding
31.91M
Market cap
$39.73M
Enterprise value
$28.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
4.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
Revenue
$9.14M
EBIT
-$35.81M
EBITDA
-$34.5M
Free cash flow
-$26.27M
Per share
Balance sheet
Liquidity
EPS
-$1.26
Free cash flow per share
-$0.87
Book value per share
$2.31
Revenue per share
$0.3
TBVPS
$1.81
Total assets
$80.7M
Total liabilities
$8.3M
Debt
$2.58M
Equity
$72.4M
Working capital
$42.91M
Debt to equity
0.04
Current ratio
9.09
Quick ratio
8.56
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
-377.5%
Gross margin
59.8%
Net margin
-411.2%
Operating margin
-423.6%
Return on assets
-40.5%
Return on equity
-44.7%
Return on invested capital
-73.9%
Return on capital employed
-47.5%
Return on sales
-391.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CODX stock price
How has the Co-Diagnostics stock price performed over time
Intraday
-1.97%
1 week
2.05%
1 month
2.89%
1 year
13.18%
YTD
-6.39%
QTD
-0.4%
Financial performance
How have Co-Diagnostics's revenue and profit performed over time
Revenue
$9.14M
Gross profit
$5.47M
Operating income
-$38.7M
Net income
-$37.57M
Gross margin
59.8%
Net margin
-411.2%
The company's gross profit has surged by 98% QoQ and by 8% YoY
Co-Diagnostics's gross margin has increased by 45% QoQ but it has decreased by 14% YoY
Co-Diagnostics's operating margin has increased by 43% YoY and by 34% from the previous quarter
The revenue has grown by 37% from the previous quarter and by 25% YoY
Growth
What is Co-Diagnostics's growth rate over time
Valuation
What is Co-Diagnostics stock price valuation
P/E
N/A
P/B
0.54
P/S
4.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.11
CODX's EPS is up by 4.5% since the previous quarter
The P/B is 84% below the 5-year quarterly average of 3.4 but 38% above the last 4 quarters average of 0.4
The equity has declined by 30% year-on-year and by 8% since the previous quarter
The P/S is 68% below the 5-year quarterly average of 13.1 and 22% below the last 4 quarters average of 5.4
The revenue has grown by 37% from the previous quarter and by 25% YoY
Efficiency
How efficient is Co-Diagnostics business performance
CODX's return on sales is up by 40% year-on-year and by 34% since the previous quarter
CODX's return on equity is down by 37% year-on-year and by 5% since the previous quarter
The ROA has contracted by 34% YoY and by 4.9% from the previous quarter
CODX's return on invested capital is up by 7% year-on-year but it is down by 6% since the previous quarter
Dividends
What is CODX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CODX.
Financial health
How did Co-Diagnostics financials performed over time
The current ratio has decreased by 40% YoY and by 11% from the previous quarter
Co-Diagnostics's quick ratio has decreased by 38% YoY and by 10% QoQ
The company's debt is 96% lower than its equity
The debt to equity is up by 33% year-on-year
The equity has declined by 30% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.